NovaBridge Biosciences (NBP) Revenue (2022 - 2023)
NovaBridge Biosciences' (NBP) quarterly Revenue came in at $5000.0 in Q4 2023, down 99.67% year-on-year from $1.5 million in Q4 2022, and down 98.41% on a QoQ basis from $315000.0 in Q3 2023.
NovaBridge Biosciences (NBP) Revenue (2022 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has 2 years of Revenue data on file, last reported at $5000.0 in Q4 2023.
- On a quarterly basis, Revenue fell 99.67% year-over-year to $5000.0 in Q4 2023; TTM through Dec 2023 was $2.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $632000.0, down 59.25% from the prior year.
- Revenue for Q4 2023 stood at $5000.0, down from $315000.0 in the prior quarter.
- Over the last five years, Revenue for NBP reached as high as $1.5 million in Q4 2022 and fell as low as $5000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | NovaBridge Biosciences | 389.86 Mn | 389.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 5,000.00 |
| Sep 30, 2023 | 315,000.00 |
| Jun 30, 2023 | 159,000.00 |
| Dec 31, 2022 | 1.50 Mn |